secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001437749-24-001326
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart CEO resigns; receives $9.27M U.S. contract for oral XBB vaccine trial
----------------------------------------------------------------------------

- CEO Andrei Floroiu resigns as President, CEO, and board member effective Jan 15, 2024.
- Board Chair Michael J. Finney appointed Interim CEO; receives $595k base salary, 50% bonus target.
- Company awarded $9.27M U.S. govt. contract (ASPR) for planning Phase 2b trial of oral XBB vaccine vs. mRNA.
- Dr. David Wheadon appointed Lead Director with $25k annual retainer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/0001437749-24-001326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924001326/vxrt20240115_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer